MedPath

Changzhou Qianhong Biopharma Co.,Ltd

Ownership
-
Established
2003-04-30
Employees
900
Market Cap
-
Website
www.qhsh.com.cn
Introduction

The company is a leading manufacturer and operator of polysaccharides and protease drugs in the domestic biochemical pharmaceutical industry. It is a national high-tech enterprise and a key key enterprise in the national three pharmaceutical bases. It has won the title of national, provincial and municipal drug quality integrity demonstration enterprise for many years in a row. The company's main business scope: licensing projects: pharmaceutical production; drug contract production; drug wholesale; drug retail; drug import/export (projects requiring approval according to law can only be carried out business activities after approval by relevant departments; specific business projects are subject to approval). The company's main products are two major biochemical drugs, active enzymes and polysaccharides. Corporate honors: advanced units, advanced enterprises, key enterprises, priority grass-roots trade union organizations, model workers' homes, etc.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

58

NMPA:58

Drug Approvals

Nadroparin Calcium Injection

Product Name
那屈肝素钙注射液
Approval Number
国药准字H20247012
Approval Date
Mar 1, 2024
NMPA

Heparin Sodium Injection for Lock Flush

Product Name
肝素钠封管注射液
Approval Number
国药准字H20227026
Approval Date
Mar 8, 2022
NMPA

Dalteparin Sodium Injection

Product Name
达肝素钠注射液
Approval Number
国药准字H20153300
Approval Date
Nov 9, 2020
NMPA

Dalteparin Sodium

Product Name
达肝素钠
Approval Number
国药准字H20153299
Approval Date
Nov 9, 2020
NMPA

Lyophilizing Thrombin Powder

Product Name
凝血酶散
Approval Number
国药准字H32021165
Approval Date
Jun 15, 2020
NMPA

Adenosine Disodium Triphosphate for Injection

Product Name
注射用三磷酸腺苷二钠
Approval Number
国药准字H32022087
Approval Date
Jun 15, 2020
NMPA

Heparin Sodium Injection

Product Name
肝素钠注射液
Approval Number
国药准字H32022089
Approval Date
Jun 15, 2020
NMPA

Chondroitin Sulfate Injection

Product Name
硫酸软骨素注射液
Approval Number
国药准字H32026363
Approval Date
Jun 15, 2020
NMPA

Heparin Sodium

Product Name
肝素钠
Approval Number
国药准字H32022021
Approval Date
Jun 15, 2020
NMPA

Urokinase for Injection

Product Name
注射用尿激酶
Approval Number
国药准字H32022096
Approval Date
Jun 15, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.